SCHEMBL4013129

SCHEMBL4013129

O=C(NCc1ccc(F)cc1)c1ccc(S(=O)(=O)n2nc(C3CCCC3)c3ccccc32)cc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.48
CXCR4 P61073 1/20 0.48
RORC P51449 3/20 0.45
PTGER4 P35408 1/20 0.44
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
MAPT P10636 2/20 0.42
USP5 P45974 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
CCR1 P32246 1/20 0.42
TGM2 P21980 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
TSHR P16473 1/20 0.41
LMNA P02545 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4002900 0.91 CCR1 (0.49) ALDH1A1CXCR4RORCPTGER4USP5
SCHEMBL5010366 0.85 CA2 (0.48) ALDH1A1RORCUSP5LMNA
SCHEMBL5006331 0.83 USP5 (0.41) ALDH1A1RORCMEN1KMT2AUSP5
SCHEMBL4006291 0.83 CXCR4 (0.53) ALDH1A1CXCR4RORCPTGER4MEN1
SCHEMBL4013046 0.82 ALDH1A1 (0.53) ALDH1A1CXCR4PTGER4MEN1KMT2A
SCHEMBL4012307 0.81 CXCR4 (0.53) ALDH1A1CXCR4RORCPTGER4L3MBTL1
SCHEMBL4007300 0.81 CXCR4 (0.53) ALDH1A1CXCR4RORCPTGER4MEN1
SCHEMBL5005889 0.81 LMNA (0.46) ALDH1A1USP5TGM2TSHRLMNA
SCHEMBL1413569 0.81 HTR6 (0.55) ALDH1A1CXCR4RORCMEN1KMT2A
SCHEMBL5411251 0.80 MEN1 (0.53) MEN1KMT2AMAPTCYP2C9L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7595339-B2 CB1 modulator compounds ELI LILLY AND COMPANY (US) 2009-09-29 US disclosed
US-7595339-B2 CB1 modulator compounds ELI LILLY AND COMPANY (US) 2009-09-29 US disclosed
US-7595339-B2 CB1 modulator compounds ELI LILLY AND COMPANY (US) 2009-09-29 US disclosed
US-20080287504-A1 CB1 MODULATOR COMPOUNDS ALLEN JENNIFER REBECCA 2008-11-20 US disclosed
US-20080287504-A1 CB1 MODULATOR COMPOUNDS ALLEN JENNIFER REBECCA 2008-11-20 US disclosed
US-20080287504-A1 CB1 MODULATOR COMPOUNDS ALLEN JENNIFER REBECCA 2008-11-20 US disclosed
US-7276516-B2 CB1 antagonist compounds ELI LILLY AND COMPANY (US) 2007-10-02 US disclosed
US-7276516-B2 CB1 antagonist compounds ELI LILLY AND COMPANY (US) 2007-10-02 US disclosed
US-7276516-B2 CB1 antagonist compounds ELI LILLY AND COMPANY (US) 2007-10-02 US disclosed
US-20070088018-A1 Cb1 antagonist compounds ELI LILLY AND COMPANY (US) 2007-04-19 US disclosed
US-20070088018-A1 Cb1 antagonist compounds ELI LILLY AND COMPANY (US) 2007-04-19 US disclosed
US-20070088018-A1 Cb1 antagonist compounds ELI LILLY AND COMPANY (US) 2007-04-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070088018-A1 Cb1 antagonist compounds CNR1, CNR2, CHRNA5 ALDH1A1 3227/4885CXCR4 690/4885RORC 2641/4885
US-20080287504-A1 CB1 MODULATOR COMPOUNDS CNR1, CNR2, MAG ALDH1A1 3181/4885CXCR4 768/4885RORC 2351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.